The results of clinical, experimental, and genetic data indicate that PCSK9 might be influenced by several metabolic and lipid risk factors, including atherogenic lipoproteins, obesity, and insulin resistance [12, 14]. This evidence concerns the gene PCSK9 and Insulin resistance.